What medications can be taken with Valsartan (angiotensin II receptor antagonist)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medications That Can Be Taken with Valsartan

Valsartan can be safely combined with many medications including beta-blockers, calcium channel blockers, diuretics, statins, and certain heart failure medications, but requires careful monitoring when combined with medications that affect potassium levels or renal function. 1

Compatible Medication Classes

Diuretics

  • Hydrochlorothiazide is commonly combined with valsartan for enhanced blood pressure control
  • Fixed-dose combinations of valsartan/hydrochlorothiazide have demonstrated superior efficacy compared to individual components 2
  • Monitor for electrolyte imbalances, particularly potassium levels

Beta-Blockers

  • Can be safely combined with valsartan for hypertension and heart failure management
  • Examples: metoprolol, carvedilol
  • Valsartan can be given with other standard post-myocardial infarction treatments including beta-blockers 1
  • Monitor for hypotension, especially during initiation

Calcium Channel Blockers

  • Amlodipine can be safely combined with valsartan
  • No clinically significant pharmacokinetic interactions observed when valsartan was coadministered with amlodipine 1
  • Initial amlodipine dose: 2.5-5 mg daily; maximum: 10 mg daily 3

Statins

  • Valsartan can be administered with statins for cardiovascular risk reduction
  • When combining with sacubitril/valsartan, lower doses of statins may be considered due to potential interactions 4
  • Monitor for muscle-related symptoms if combining with statins

Heart Failure Medications

  • Ivabradine: No clinically significant interactions reported 4
  • Digoxin: No clinically significant pharmacokinetic interactions observed 1
  • Sacubitril (in fixed combination with valsartan): Used in place of valsartan alone in heart failure

Medications Requiring Caution

Potassium-Sparing Agents

  • Mineralocorticoid receptor antagonists (spironolactone, eplerenone): Increased risk of hyperkalemia
  • Avoid in patients with serum creatinine >2.5 mg/dL or serum K+ >5.0 mmol/L 4
  • Potassium supplements: Monitor serum potassium levels closely 4

NSAIDs

  • May reduce antihypertensive effect of valsartan
  • Can worsen renal function when combined with valsartan
  • Use lowest effective dose for shortest duration if combination necessary

Other Considerations

  • ACE inhibitors: Generally not recommended to combine with valsartan as this combination may increase adverse effects without additional benefits 4
  • Medications affecting OATP1B1, OATP1B3, OAT1, and OAT3 transporters: May increase valsartan exposure 1

Monitoring Recommendations

  1. Blood Pressure: Monitor within 1-2 weeks after initiation or dose changes 3
  2. Renal Function: Check within 1-2 weeks after starting combination therapy, particularly in patients with:
    • Pre-existing hypotension
    • Hyponatremia
    • Diabetes mellitus
    • Renal impairment 3
  3. Potassium Levels: Regular monitoring when combining with medications that affect potassium (diuretics, potassium supplements, potassium-sparing agents) 4

Special Populations

  • Elderly: Exposure to valsartan is higher by 70% and half-life is longer by 35% in elderly patients 1
  • Hepatic Impairment: Patients with mild-to-moderate chronic liver disease have twice the exposure to valsartan 1
  • Renal Impairment: No dose adjustment needed based on renal function, but monitor closely 1

Common Pitfalls to Avoid

  1. Combining ACE inhibitors with valsartan and aldosterone antagonists (triple combination) can increase risk of hyperkalemia and renal dysfunction 3
  2. Failure to monitor potassium levels when combining with potassium-sparing medications
  3. Not adjusting doses in elderly patients who may have increased sensitivity to valsartan
  4. Overlooking potential interactions with transporters (OATP1B1, OATP1B3, OAT1, OAT3) that may affect statin levels 4

Valsartan's favorable drug interaction profile makes it compatible with many cardiovascular medications, allowing for effective combination therapy in hypertension, heart failure, and post-myocardial infarction management.

References

Research

Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy.

Expert opinion on drug metabolism & toxicology, 2009

Guideline

Hypertension Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.